Eltrombopag Improves Platelet Count in Pediatric HIV

Author(s):

Elissa Engel, MD

Eltrombopag (Promacta) boosted the platelet count in a 13-year-old boy with HIV-associated thrombocytopenia, according to case study results presented at the 2018 American Society of Pediatric Hematology/Oncology Conference (ASPHO), held May 2-5 in Pittsburgh, Pennsylvania.¹ The findings are important because thrombocytopenia is a common hematologic event in pediatric HIV.

“After initiation of this mediation at 50 mg per day, [the child] showed a sustained improvement in his platelet count and has so far been free of symptomatic thrombocytopenia,” lead author Elissa Engel, MD, a second-year pediatric resident at the University of South Florida (USF), told OncLive^®.

The patient had previously failed on first-line treatment with IV immunoglobin and antiretroviral optimization.

The FDA approved oral eltrombopag, a thrombopoietin receptor agonist that stimulates bone marrow megakaryocytes to produce platelets, in November 2008 for treatment of thrombocytopenia in patients with idiopathic thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Thrombocytopenia was observed in 29 (8.5%) of 339 children with HIV in a 14-year study that evaluated for prevalence of the condition.²Chronic and acute thrombocytopenia were observed in 22 and 7 children, respectively.

At ASPHO, Engel delivered the findings of a retrospective chart review in a poster. The patient in question was diagnosed with HIV after he experienced several incidents of thrush. At baseline, his white blood cell count was 1500 with a CD4 T cell count <1%. His HIV viral load was >50,000 copies/mL and he had a platelet count of 18,000.

His viral load was undetectable after 3 months of antiretroviral treatment with lamivudine/zidovudine (Combivir) and Iopinavir/ritonavir (Kaletra), but physicians were unable to resolve his thrombocytopenia. Physicians switched him to a combination of dolutegravir (Tivicay), abacavir (Ziagen), and emtricitabine (Emtriva) because that regimen has been associated with a lower incidence of thrombocytopenia.

The patient received infusions of IV immunoglobin on a near-monthly basis, but his response was short-lived and the treatment reduced his quality of life.

Physicians then initiated 50 mg of daily eltrombopag in hopes of maintaining a platelet count ≥10,000. The patient achieved a sustained platelet count of 32,000 to 88,000 with no significant adverse events (AEs).

Eltrombopag is rarely prescribed for pediatric patients because the drug has a black box warning for hepatotoxicity, Engel explained. When used in combination with interferon and ribavirin, eltrombopag has been associated with increased risk for hepatotoxicity, which can aggravate underlying cardiopulmonary disease and increase the risk for death.³

Physicians at USF decided to move forward with eltrombopag based on results from the PETIT and PETIT2 trials involving children with persistent and chronic immune thrombocytopenia.^4,5

PETIT was a 3-part, randomized, multicenter, placebo-controlled study trial conducted at 22 medical centers. Investigators recruited patients aged 1 to 17 years with immune thrombocytopenia lasting ≥6 months and platelet count less than 30 × 10⁹/L who were relapsed/refractory to at least 1 previous treatment or who were ineligible for other treatments because of a medical disorder.

Part 1 was a dose-finding phase in which patients received open-label eltrombopag for 24 weeks. In the double-blind part 2, patients were randomly assigned to eltrombopag or placebo for 7 weeks. Part 2 included additional patients not treated in the dose-finding phase.

In the open-label part 3, patients who previously received eltrombopag stayed on-treatment for 17 additional weeks while those who had previously received placebo were assigned to 24 weeks of eltrombopag.

The proportion of patients who had a platelet count of ≥50 × 10⁹/ L at least once during weeks 1 to 6 of the randomized phase of the study without rescue therapy was the primary endpoint. Forty-five patients were assigned to eltrombopag and 22 were assigned to placebo.

During part 2, 62% (n = 28) of patients assigned to eltrombopag achieved the primary endpoint compared with 32% (7) of those assigned to placebo (odds ratio [OR], 4.31, 95% CI, 1.39-13.34, P = .011). Thirteen patients (29%) assigned to eltrombopag maintained responses through week 6 compared with only 1 (5%) patient in the placebo group. Eleven (24%) patients in eltrombopag group had a continuous response for more than 3 weeks compared with zero patients assigned to placebo, according to post-hoc analysis.

PETIT2 was a 2-part, randomized, multicenter, placebo-controlled trial conducted at 38 facilities in 12 countries. Patients aged 1 to 17 years who had chronic immune thrombocytopenia and platelet counts less than 30×10⁹/L were randomly assigned to eltrombopag (n = 63) or placebo (n = 29). A total of 59 (94%) patients assigned to eltrombopag and 28 (97%) assigned to placebo completed the double-blind period and proceeded to the open-label treatment phase. Fifty-five (87%) patients assigned to eltrombopag and 25 (86%) assigned to placebo finished the open-label treatment period.

Due to increased plasma eltrombopag exposures, patients of East Asian ancestry received a lower starting dose. East Asian patients aged 6 to 17 years were assigned to 25 mg/day.

Patients aged 6 to 17 years weighing 27 kg or more started treatment at 50 mg/day and those weighing less than 27 kg started treatment at 37.5 mg/day.

The proportion of patients achieving platelet counts ≥50 × 10⁹/L without rescue therapy for ≥6 weeks after weeks 5 to 12 of the double-blind period was the primary endpoint.

Twenty-five (40%) patients assigned eltrombopag achieved the primary endpoint compared with 1 (3%) assigned to placebo (OR, 18.0; 95% CI, 2.3-140.9; P = .0004).

Engel said it would difficult to evaluate eltrombopag in a clinical trial because the population of pediatric patients with HIV is small and the number of those patients with thrombocytopenia is smaller still. She said it might be possible to build a larger trial through a database of patients across multiple institutions, and this report represents just “the beginning efforts” of such research.

References

Engel E, Soliman M, Rico J, et al. Successful use of eltrombopag in a pediatric patient with HIV-related thrombocytopenia. Presented at: the 2018 ASPHO Conference; May 2-5, 2018; Pittsburgh, PA. Poster 056.
Barboni G, Candi M, Bayon M, Babaryski J, Gaddi E. [Prevalence of thrombocytopenia in HIV infected children]. Medicina (B Aires). 2010;70(5):421-426.
Promacta [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017. pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/promacta.pdf. Accessed May 7, 2018.
Bussel JM, de Miguel PG, Despotovic JM, et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015;2:e315—25. doi: 10.1016/S2352-3026(15)00114-3.
Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;386(10004):1649-1658. doi: 10.1016/S0140-6736(15)61107-2.

<<< 2018 ASPHO Conference